Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement is a paper indexed in PICO Portal from OpenAlex.
How many citations does Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement have?
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement has 298 citations in the OpenAlex counts PICO Portal stores.
When was Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement published?
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement has 2017 year in the PICO Portal index.
What is the open-access status of Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement?
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement has green oa status in the PICO Portal index.
What is the DOI of Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement?
The DOI for Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement is on the source record.
What is the PMID of Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement?
The PMID for Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement is on the source record.
What is the OpenAlex record for Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement?
The OpenAlex for Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement is on the source record.